Darolutamide now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ...

CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

The MarketWatch News Department was not involved in the creation of this content. -- Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with ...

Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...

Apalutamide in patients with metastatic hormone-sensitive prostate cancer: Real-world experience and a retrospective multicenter analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

K36 to initiate first-in-human Phase 1 clinical study evaluating KTX-2001 as monotherapy and in combination with darolutamide in mCRPC patients K36 is working with The Prostate Cancer Clinical Trials ...

Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.